Biotech/Pharmaceuticals Analysts, along with Dr. Frederic Colombel of Mount Sinai discuss Ventyx Biosciences (VTYX) VTX002 Phase 2 Ulcerative Colitis Clinical Trial Results, key endpoints and implications on adoption on an Analyst/Industry conference call to be held on October 26 at 12 pm.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VTYX:
- Oppenheimer biotech/pharma analysts hold analyst/industry conference call
- Ventyx Biosciences director Subramaniam sells nearly 50,000 common shares
- Ventyx Biosciences price target lowered to $47 from $65 at Evercore ISI
- Ventyx Biosciences price target lowered to $56 from $57 at Oppenheimer
- Ventyx Biosciences Phase 2 trial of VTX002 for UC meets primary endpoint
